Skip to main content

Table 2 Secondary outcomes

From: LIHNCS - Lugol’s iodine in head and neck cancer surgery: a multicentre, randomised controlled trial assessing the effectiveness of Lugol’s iodine to assist excision of moderate dysplasia, severe dysplasia and carcinoma in situ at mucosal resection margins of oral and oropharyngeal squamous cell carcinoma: study protocol for a randomised controlled trial

  Secondary outcome measures:
1. Acceptability of the technique to surgeons carrying out surgery for oral and oropharyngeal carcinoma.
2. Effect of Lugol’s technique on any further treatment carried out (radiotherapy, chemoradiotherapy or further surgery).
3. Estimate of the two-year locoregional recurrence rates in each group.
4. Mean and range of volume of tissue removed by each method.
5. Safety of the technique.
6. Assessment of quality of life changes using EORTC QLQ-30 and EORTC-35 H&N questionnaires, and the MD Anderson Dysphagia Inventory (MDADI) questionnaire
7. Overall survival